Clinical studies show elevated levels of mPGES-1 are identified in colon, lung, stomach, pancreas, cervix, prostate, papillary thyroid carcinoma, head and neck squmaous carcinoma and brain tumors, suggesting mPGES-1 inhibitors might be a potential chemopreventive agent [16]. This evidence concerns the gene PTGES and thyroid gland papillary carcinoma.